New hope for lung transplant patients: drug may block dangerous virus
NCT ID NCT05041426
First seen Apr 14, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study tested whether the drug letermovir can prevent CMV (a common virus) infection in adults who had a lung transplant due to idiopathic pulmonary fibrosis. Fifteen participants received letermovir, and researchers tracked how many developed CMV during treatment and in the three months after. The goal was to see if this drug could safely reduce infection risk in this vulnerable group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.